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Survival rates for patients with glioblastoma 
multiforme (GBM), the most common malignant brain 
tumor, remain dismal despite decades of basic and clinical 
research. New treatment strategies are desperately needed. 
Consequently, the high-throughput genomic technologies 
developed to facilitate examination of cancer genomes 
have recently been focused on GBM, with goals of 
identifying novel molecular targets and developing a 
clinically-relevant biological classification of this deadly 
cancer. 
These genomic analyses have provided an 
unprecedented view of the complex genetic landscape 
of  GBM,  confirming  the  central  role  of  both  well-
established and previously-unsuspected genes in the 
development of these tumors [1,2]. In addition, despite 
the plethora of genes found to be altered in GBMs, these 
data have allowed a semblance of order to be applied to 
these tumors through the identification of a small number 
of core pathways critical to GBM pathogenesis and the 
elucidation of discrete molecular subgroups of GBM [3]. 
The list of biologically-relevant GBM genes remains 
incomplete, however, due in large part to the logistical 
challenge  of  establishing  the  functional  significance 
of the numerous genes found to be infrequently altered 
(between 1 and 5%) in these cancers. 
The detection of focal regions of recurrent copy 
number  gain  or  loss  (amplifications  or  homozygous 
deletions) can be a useful tool for the identification of 
candidate cancer genes. Using such a high-resolution 
genomic  approach,  Duncan  et  al.  have  identified  two 
genes as potentially relevant to the emerging picture of 
the GBM genome, ERRFI1 (located at chr1p36) and 
TACC3 (located at chr4p16) [4]. Genomic alterations 
in these two regions have been reported in a number of 
human  cancers,  but  the  specific  target  genes  of  these 
copy number alterations are not known. The Digital 
Karotyping and SNP array data provided by Duncan et 
al. have provided initial evidence for two reasonable 
candidates. Importantly, given the significant challenge 
of distinguishing between altered genes which are drivers 
(i.e. genes that contribute to tumorigenesis) and those 
that are merely passengers (i.e. genes that accumulate 
alterations during tumor development but are not 
biologically relevant), preliminary studies of the potential 
functional significance of the candidate genes have been 
conducted.
Recurrent focal deletions at 1p36, previously 
reported in numerous cancers including GBM, were 
found by Duncan et al. in their cohort of GBMs and 
validated using data from The Cancer Genome Atlas 
(TCGA) project. Two distinct minimal deleted regions 
were identified, with the most commonly-deleted region 
containing a single gene, ERRFI1. ERRFI1 expression 
was also found to be downregulated in ~34% of GBM 
samples analyzed, and functional studies of a cell line 
with a homozygous deletion of ERRFI1 revealed impaired 
wound-healing and a lower rate of trans-well migration 
after transfection with a vector containing ERRFI1, 
suggesting ERRFI1 as a potential tumor suppressor gene 
in GBMs. Similarly, focal gains at 4p16, most commonly 
involving  TACC3, and overexpression of TACC3 were 
found in tumor samples, raising the possibility of TACC3 
as a potential GBM oncogene.
Both of these genes are biologically-plausible as 
GBM-related candidates. ERRFI1 acts as a negative 
regulator of EGFR and the ERbB family, while 
dysregulation of TACC (transforming acidic coiled 
coil) genes, components of the centrosome, has been 
implicated  in  cancer  development.  Significant  work 
remains, however, in order to confirm the relevance of 
these genes for the pathogenesis of GBM and identify 
them as potential targets of molecular therapeutics. In 
particular, additional functional data firmly establishing 
the genes as “drivers” and demonstrating their specific 
biological role in GBM development are required. In 
addition, clarification of how these genomic data fit in 
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GBM will be illuminating: for example, are alterations of 
ERRFI1 specifically identified in the subgroup of GBMs 
with downstream evidence of EGFR activation that lack 
EGFR  amplification  or  mutation  [3]?  Further  research 
building on the foundation of this intriguing genomic data 
will surely add to our evolving picture of the glioblastoma 
genome. Hopefully it will also contribute to the improved 
care of our patients with these deadly cancers.
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